In different rodent models of hypertension, vascular voltagegated L-type calcium channel (Ca L ) current and vascular tone is increased because of increased expression of the noncardiac form of the Ca L (Ca v 1.2). The objective of this study was to develop a small interfering RNA (siRNA) expression system against the noncardiac form of Ca v 1.2 to reduce its expression in vascular smooth muscle cells (VSMCs). siRNAs expressing plasmids and appropriate controls were constructed and first screened in human embryonic kidney (HEK) 293 cells cotransfected with a rat Ca v 1.2 expression vector. The most effective gene silencing was achieved with a modified mir-30a-based short hairpin RNA (shRNAmir) driven by the cytomegalovirus promoter. In A7r5 cells, a vascular smooth muscle cell line, two copies of shRNAmir driven by a chimeric VSMC-specific enhancer/promoter reduced endogenous Ca v 1.2 expression by 61% and decreased the Ca L current carried by barium by 47%. Moreover, the chimeric vascular smooth muscle-specific enhancer/promoter displayed almost no activity in non-VSMCs (PC-12 and HEK 293). Because the proposed siRNA was designed to only target the noncardiac form of Ca v 1.2, it did not affect the Ca L expression and function in cultured cardiomyocytes, even when driven by a stronger cytomegalovirus promoter. In conclusion, vascular Ca v 1.2 expression and function were effectively reduced by VSMC-specific delivery of the noncardiac form of Ca v 1.2 siRNA without similarly affecting cardiac Ca L expression and function. When coupled with a viral vector, this molecular intervention in vivo may provide a novel longterm vascular-specific gene therapy for hypertension.
One hallmark finding in chronic hypertension is an anomalous constriction of small arteries and arterioles that is mediated by Ca 2ϩ influx through Ca L (Ca v 1.2). Ca v 1.2 expression is increased in the renal, mesenteric, and skeletal muscle circulations of different rodent models of hypertension, and the increased expression corresponds to a higher density of Ca L current and the development of anomalous vascular tone (Ohya et al., 1993; Lozinskaya and Cox, 1997; Pratt et al., 2002; Pesic et al., 2004) . In smooth musclespecific Ca v 1.2 knockout mice, depolarization-induced contraction and myogenic tone were abolished, and the mean blood pressure was reduced by ϳ30 mm Hg (Moosmang et al., 2003) . These studies demonstrate collectively a strong, positive correlation between blood pressure and the number of Ca L in the arterial circulation in vivo. Thus, high blood pressure may be amenable to control by therapeutic interventions that down-regulate Ca v 1.2 expression in the vasculature.
Ca v 1.2 is expressed in many tissues including heart, brain, lung, uterus, the gastrointestinal system, and VSMCs (Koch et al., 1990) . Several alternatively spliced isoforms have been identified. It is notable that alternative splicing of exon 1 results in two different N termini of Ca v 1.2 (isoforms A and B) that are conserved in many species. Isoform A (cardiac form) is specifically expressed in the heart, whereas isoform B (noncardiac form) is ubiquitously expressed in many cell types, including VSMCs (Dai et al., 2002; Pang et al., 2003; Saada et al., 2003 Saada et al., , 2005 Tang et al., 2007) . Ca v 1.2 isoform B is the main isoform up-regulated in the arteries of spontaneously hypertensive rats (SHRs) compared with their normotensive controls, but the total expression level of Ca v 1.2 does not change in SHR hearts (Wang et al., 2006a ), presumably because the expression level of isoform B (both mRNA and protein) in the heart is far less than isoform A (Dai et al., 2002; Pang et al., 2003; Saada et al., 2003 Saada et al., , 2005 Tang et al., 2007) . Thus, our goal in this study is to design an siRNA expression vector that can preferentially knock down the expression of the noncardiac form of Ca v 1.2 in VSMCs without affecting the cardiac Ca v 1.2 expression in the heart, where Ca L activity is crucial for excitation-contraction coupling. Using this molecular intervention to reduce the abnormal expression of Ca L in VSMCs rather than attempting to block Ca 2ϩ influx may represent a new way to treat hypertension because it may offer even higher vascular selectivity and fewer side effects than traditional calcium channel blockers.
Materials and Methods
Plasmids. The short hairpin RNA (shRNA) expression vectors U6-shRNA1-green fluorescent protein (GFP) and modified cytomegalovirus (mCMV) promoter-shRNA1-GFP (Fig. 1A) were prepared using the commercial siRNA expression vectors pRNAT-U6.1/Neo and pRNAT-CMV3.1/Neo (GenScript, Piscataway, NJ), which contain either a human U6 promoter-or a mCMV promoter-driven siRNA expression cassette and an RNA polymerase (pol) II promoterdriven marker gene-GFP. The oligonucleotide shRNA1 has the following sequence: 5Ј-CTC TGG AAC GTA CAT CCT CGT TTC AAG AGA ACG AGG ATG TAC GTT CCA GAG-3Ј, where the antisense strand (the proposed siRNA strand) is underlined, and the stem loop sequence is in italics. The CMV-EGFP-shRNA1 ( Fig. 2A ) was prepared by inserting a translational stop codon and shRNA1 into pEGFP-C1's (Clontech, Mountain View, CA) multiple cloning sites (Ling and Li, 2004; Yuan et al., 2006) . The microRNA (miRNA) mir-30a-based shRNA constructs (CMV-EGFP-shRNAmir, Fig. 2B ) were prepared by incorporating the siRNA encoding sequences into the mir-30a backbone and then placing them at the 3Ј-untranslated region (UTR) of pEGFP-C1. All the shRNA inserts were chemically synthesized by Integrated DNA Technologies, Inc. (Coralville, IA).
The Ca v 1.2 siRNA-targeting sequences were carefully selected among the 100% homologous region of mouse and rat Ca v 1.2 exon 1b sequences (GenBank accession no. L01776, nucleotides 1109 -1215; M67516, nucleotides 697-803), which would only target the noncardiac isoform. Similarity search of candidate siRNA against the mRNA sequences of both mouse and rat was conducted using the BLAST program (National Center for Biotechnology Information, Bethesda, MD). The truncated mouse SM22␣ promoter was amplified by polymerase chain reaction from plasmid pBluescript-SM22␣ (kindly provided by Dr. Joseph Miano, University of Rochester Medical Center, Rochester, NY) with forward primer, 5Ј-AGCT ATT AAT GGA TC CTC GAG TAG TCA AGA CTA GTT CCC ACC AA-3Ј, and reverse primer, 5Ј-TCAG GCT AGC GAA GGA GAG TAG CTT CGG TGT-3Ј (underlined nucleotides represent restriction sites used for subcloning). The rabbit myosin heavy-chain enhancer (GenBank accession no. X79928; nucleotides 973-1084) was chemically synthesized by Integrated DNA Technologies, Inc. and inserted in front of the SM22␣ promoter with AseI and XhoI. The shRNAmir constructs with the chimeric smooth muscle-specific enhancer/promoter (EnSM22␣) were prepared by replacing the CMV promoter of CMV-EGFP-shRNAmir with AseI-and NheI-digested EnSM22␣. The correct inserts of each plasmid were verified by sequencing.
Cell Culture and Transfection. cence microscopy and verified by flow cytometry (Cell Lab Quanta; Beckman Coulter, Fullerton, CA). Western blots were performed only when Ն70% of cells were transfected.
Patch Clamp of Ca L Current. Three days post-transfection, HL-1 or A7r5 cells were trypsinized and resuspended in control Hanks' balanced salt solution (HBSS) of the following composition: 145 mM NaCl, 5.4 mM KCl, 1 mM CaCl 2 , 1 mM MgCl 2 , 10 mM HEPES, and 5.5 mM dextrose. The cells were placed in a glass bottom dish and allowed to attach to the bottom at room temperature. The dish was placed on the stage of an inverted microscope and perfused with control HBSS. To measure Ca L current, cells were externally perfused with 20 mM barium HBSS (both sodium-and potassium-free with 110 mM N-methyl-D-glucamine substitution) and internally with 150 mM cesium, 120 mM aspartate, 30 mM chlorine, 1 mM calcium, 5 mM magnesium, 11 mM EGTA, 10 mM HEPES, 5 mM ATP, 0.5 mM GTP, 5 mM creatine phosphate, and 5 mM pyruvate. Osmolarity of all solutions was 290 to 310 mOsm, and pH of external and internal solutions was adjusted to 7.4 and 7.2, respectively. All experiments were performed at room temperature (20 -22°C).
Electrophysiological measurements were made using conventional techniques and methods described previously (Harrell and Stimers, 2002) . Data obtained in response to voltage pulses were low-pass filtered by either analog or digital filters at 1 kHz and sampled at 2 kHz. Patch pipettes were made from borosilicate glass (Corning Inc., Corning, NY) pulled on a Brown-Flaming P77 puller (Sutter Instrument Company, Novato, CA) and fire polished to have a final resistance of 3 to 5 M⍀ (inside tip diameter of 1-3 m). Capacitance and series resistance compensation were used to improve the quality of the voltage clamp and reduce associated artifacts. P/4 protocols were used to cancel leak and capacitance currents when pulse protocols were applied.
Western Blots. Cultured cells were lysed with lysis buffer (50 mM NaCl, 25 mM Tris-HCl, pH 7.4, 0.5% sodium deoxycholate, 1% Ipegal (octylphenyl-polyethylene glycol), 1 mM phenylmethylsulfonyl fluoride, 2 g/ml aprotinin, and 5 g/ml leupeptin) (all from Sigma-Aldrich) 72 h post-transfection, and the supernatant was collected after a 15-min centrifugation at 10,000g. Western blots were run using Tris-acetate gradient gels (Invitrogen), transferred onto polyvinylidene difluoride membranes (G-Biosciences, Maryland Heights, MO), blocked, and probed with primary antibody for Ca v 1.2 (Alamone Labs, Jerusalem, Israel), ␣/␤-actin (Sigma-Aldrich), and IP 3 R 1 (Upstate, Lake Placid, NY). Films were scanned, and the images were quantified with an Alpha Innotech (San Leandro, CA) 8900 imager using AlphaEase FC software, version 3.2.3. Statistical Analysis. Data are reported as mean Ϯ S.E.M. Statistical comparisons were performed using one-way analysis of variance followed by post hoc Student-Newman-Keuls test. Differences were considered significant when the p value was Ͻ0.05.
Results
Comparison of Different pol II Promoter-Driven siRNA Expression Systems. shRNA driven by pol III promoters, such as the U6 and H1 promoter, has been used widely for continuous expression of siRNA. Thus, we first designed several classic U6 promoter-driven shRNA constructs against mouse and rat Ca v 1.2 isoform B and tested their efficiency in HEK 293 cells cotransfected with a plasmid that expresses rat Ca v 1.2 isoform B. We found that U6-shRNA1-GFP had the highest efficiency (Fig. 1, A, top  diagram, and B) .
However, pol III promoters cannot drive tissue-or cellspecific expression. To test the feasibility of specifically targeting VSMCs, we transferred shRNA1 into a pol II promoter-driven siRNA expression vector (mCMV-shRNA1-GFP, Fig. 1A, bottom diagram) . The CMV promoter of this vector was modified by removing the 5Ј-UTR, and the hairpin was placed immediately behind the CMV transcription start site followed by a synthetic minimal polyA (Xia et al., 2002) . It is unfortunate that the silencing effect of this construct was poor (less than 30%, data not shown). In addition to the poor silencing effect, because 5Ј-UTRs and even the first exon/ intron are often very important for promoter activity and/or tissue specificity, the modified CMV promoter may not be interchangeable with many tissue-or cell-specific pol II promoters. Thus, we explored other pol II promoter-driven siRNA expression systems.
CMV-EGFP-shRNA1 ( Fig. 2A) was prepared by directly placing the shRNA1 in the 3Ј-UTR of EGFP cDNA (Ling and Li, 2004; Yuan et al., 2006) . CMV-EGFP-sh1mir (Fig. 2B ) was constructed by replacing the mir-30a stem sequence with shRNA1 directly (Boden et al., 2004) , and CMV-EGFPsh2mir was constructed by incorporating a newly designed miRNA-based shRNA2 into the mir-30a backbone, with modifications of a few nucleotides. The sh2mir structure was very similar to the reported shRNAmir-luc1309 (shlucmir, Fig.  2B ), which significantly silenced firefly luciferase with either pol II or pol III promoter (Silva et al., 2005) . To make direct comparisons of the silencing effects of different expression cassettes, the shRNAmirs were also cloned into pEGFP-C1 and placed in the 3Ј-UTR of EGFP cDNA (Fig. 2B) . Cotransfection of CMV-EGFP-shlucmir with plasmids expressing firefly luciferase demonstrated that the miRNA-based shRNA expression cassette can be adapted to the pEGFP-C1-3Ј-UTR and significantly reduce luciferase activity more than 70% (data not shown). In Fig. 2 , C and D, the effects of different constructs to suppress Ca V 1.2 expression were compared with the negative control, CMV-EGFP-shlucmir, in lane 3. The silencing effect of CMV-EGFP-sh2mir (lane 4) was much stronger than CMV-EGFP-shRNA1 (lane 1) and CMV-EGFP-sh1mir (lane 2) in both HEK 293 cells and A7r5 cells.
Because several natural miRNAs exist in clusters (LagosQuintana et al., 2001; Tanzer and Stadler, 2004) , the polycistronic transcripts might be able to enhance the efficiency of target gene repression (Liu et al., 2008) . Plasmid CMV-EGFP-(sh2mir) 2 was constructed with two copies of sh2mir (Fig. 3A) . We found that CMV-EGFP-(sh2mir) 2 had more significant effects than CMV-EGFP-sh2mir in silencing endogenous Ca v 1.2 in transfected A7r5 cells (0.34 Ϯ 0.04 versus 0.58 Ϯ 0.07, p Ͻ 0.001; Fig. 3B ). The silencing effects were gene-specific insofar as they did not affect the expression levels of IP 3 R 1 and ␣-actin. 
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Smooth Muscle-Specific Knockdown of Ca v 1.2. Another critical step in developing shRNA against Ca v 1.2 as a potential antihypertensive therapy is to selectively target the vasculature using a smooth muscle-specific promoter. We chose the SM22␣ promoter because it is a widely used and well characterized vascular smooth muscle-specific promoter (Solway et al., 1995; Moessler et al., 1996; Hoggatt et al., 2002) . The truncated SM22␣ promoter (ϳ500 bp) has been shown to have similar promoter activity as the full-length one and only drive reporter gene expression in vascular smooth muscle but not in the visceral smooth muscle or vein (Moessler et al., 1996; Hoggatt et al., 2002) Because the SM22␣ promoter is a relatively weak promoter, a smooth muscle-specific enhancer from rabbit myosin heavy chain was added in front of it to enhance potency (Ribault et al., 2001 ). This EnSM22␣ has been reported to enhance the SM22␣ promoter potency and smooth muscle specificity both in vitro and in vivo (Ribault et al., 2001) . We compared the specificity and potency of CMV and EnSM22␣ promoters in driving GFP expression in VSMCs, A7r5 cells and nonVSMCs, and HL-1 and PC-12 cells. The EnSM22␣ promoter showed comparable activity as the CMV promoter (one of the strongest pol II promoters) in A7r5 cells (Fig. 4A ) but showed very limited activity in non-VSMCs, HL-1 and PC-12 cells (Fig. 4, B and C) .
Because GFP and siRNA expression were both driven by the same promoter, we could easily track and identify siRNAexpressing green cells under a fluorescent microscope and patch them. EnSM22␣-EGFP-(sh2mir) 2 reduced Ca v 1.2 expression in transfected A7r5 cells by 61% as estimated by Western blots (Fig. 5A ) and also decreased Ca L current carried by barium by 47% at ϩ20 mV in patch-clamped A7r5 cells (Ϫ2.17 Ϯ 0.36 pA/pF versus Ϫ4.18 Ϯ 1.01 pA/pF control EnSM22␣-EGFP-shLucmir, p Ͻ 0.05; Fig. 5B ). However, EnSM22␣-EGFP-(sh2mir) 2 was not effective in cotransfected HEK 293 cells because HEK 293 cells are not VSMCs. In contrast, the positive control CMV-EGFP-(sh2mir) 2 was effective (Fig. 6) .
siRNA against Ca v 1.2 Isoform B Did Not Affect Cardiac L-Type Calcium Channel Expression and Function. Similar to human and rat hearts, Ca v 1.2 isoform A is the main isoform expressed in HL-1 cells (estimated by Western blot and real-time reverse transcription-polymerase chain reaction, data not shown). To confirm the selective inhibition of noncardiac Ca V 1.2, we transfected CMV and EnSM22␣ promoter-driven shlucmir and (sh2mir) 2 constructs into the HL-1 cells (Fig. 7A ) and found no decrease in overall expression of Ca v 1.2 protein. Because of the limited expression of GFP when driven by EnSM22␣ promoter (Fig.  4B) , we were not able to visually identify the transfected cells to measure the Ca 2ϩ current and confirm the EnSM22␣-EGFP-(sh2mir) 2 effect (Fig. 7A, lane 4) . Instead, we compared the effect of CMV-EGFP-(sh2mir) 2 on the Ca L current in HL-1 cells and found no significant decrease in the 
Discussion
Chronic hypertension is a deadly disease that predisposes nearly 72 million Americans and 1 billion individuals worldwide to ventricular hypertrophy, heart failure, stroke, and end-stage renal damage. However, of those given antihypertensive drug treatment, only one third have their blood pressure normalized. Low compliance is believed to be the main reason for such a low control rate. Hypertension is a lifelong disease, but currently, all antihypertensive drugs have relatively short half-lives, and patients have to take medicine everyday or even multiple times daily. In addition, various side effects make it hard for patients to comply with their treatments (Chobanian et al., 2003; Burnier, 2006; Frishman, 2007) . In this regard, a long-term gene therapy with fewer side effects may represent a significant advance in patient adherence and blood pressure control by avoiding the inconvenience associated with daily drug administration and minimizing the blood pressure fluctuations caused by shortacting drugs. The L-type calcium channel (Ca v 1.2) is a well known target for the control of hypertension because calcium channel blockers have been used widely as antihypertensive agents in daily clinical practice. The calcium channel blockers bind to distinct but closely related sites on the Ca v 1.2 channel to reduce the open-state probability of the Ca v 1.2 channel and thereby attenuate the voltage-gated Ca 2ϩ influx that is required for vascular activation. One class of calcium channel blockers, namely, dihydropyridines (Triggle, 2003) , are more effective in the vasculature than in heart or other tissues, in part because of the voltage dependence of their binding to the channels. Alternative splicing of Ca v 1.2 and different ␤ subunit composition may also contribute to their VSMC preference. However, because of rapid onset and offset of the channel blockade, especially in the case of nifedipine, these drugs can increase sympathetic activity and cause reflex tachycardia. On the other hand, the slow-release, longacting dihydropyridines (e.g., amlodipine) usually do not evoke such unwanted counter-regulatory responses (Triggle, 2003; Eisenberg et al., 2004) . In this regard, viral vectormediated Ca v 1.2 siRNA gene therapy, which selectively reduces the abnormal expression of vascular Ca v 1.2, may be potentially superior to blocking of Ca 2ϩ influx by traditional dihydropyridines, provided that it exhibits a slow onset of action, long-term stability, and sustained vascular specificity.
siRNAs, which have higher catalytic efficiency and potency and are less susceptible to the influence of target mRNA secondary structure (Ogorelkova et al., 2006; Potera, 2007) , have gradually replaced the traditional antisense and ribozyme methods to modulate target gene expression. As a treatment for hypertension, systemic delivery of synthetic siRNA against ␤1-adrenergic receptor showed promise in reducing blood pressure and cardiac hypertrophy (Arnold et al., 2007) . Nevertheless, therapeutic use of synthetic siRNAs is limited by their rapid degradation in target cells, resulting in relatively transient gene silencing, and by the difficulties in achieving sufficient transfer rates into multiple cell types of therapeutic interest, including VSMCs, especially for in vivo applications. Most importantly, systemic delivery of siRNAs may incur serious side effects by knocking down gene expression in nontarget tissues. Pol III promoters direct high levels of gene expression; therefore, pol III promoter-driven shRNAs can produce highly efficacious, target-specific silencing. Coupled with viral vectors, a prolonged effect could be obtained. Wang et al. (2006b; Sun et al., 2008) showed that adeno-associated-virus delivery of U6 promoter-driven mineralocorticoid receptor shRNA prevented the progression of cold-induced hypertension for at least 3 weeks, which was the length of the study. He et al. (2008) reported that intravenous injection of adenovirus expressing shRNA against angiotensin-converting enzyme reduced blood pressure for more than 14 days and improved myocardial remodeling in SHRs. However, the pol III promoters have no tissue or cell specificity, and exceedingly high levels of siRNA expression increase the probability of off-target silencing and may elicit nonspecific cellular toxicity. Grimm et al. (2006) reported that the adeno-associated virus-mediated sustained high levels of siRNA expression (driven by U6 or H1 promoter) oversaturated the in vivo miRNA pathway and caused deadly liver damage, whereas expression of the siRNA from a liver-specific pol II promoter was safe and effective (Giering et al., 2008) because the tissue-specific pol II promoters are less active than ubiquitously expressed pol III promoters. To determine the best strategy to selectively deliver the therapeutic siRNA to the VSMCs, we screened several pol II promoter-driven siRNA expression systems and found that a modified mir-30a-based shRNA structure (sh2mir) mediated the most effective silencing (Fig. 2) . miRNAs are a recently recognized class of highly conserved, noncoding short RNA molecules (approximately 22 nucleotides) that regulate gene expression at the post-transcriptional level. The maturation of miRNA is mediated by two RNase III endonucleases, Dicer and Drosha, and the mature miRNA functions as siRNA; the single-stranded guide RNA (siRNA strand) incorporates into the RNA-induced silencing complex and directs target gene silencing. Because miRNAs can down-regulate gene expression at the post-transcriptional level, and most miRNAs are transcribed by pol II promoters, mimicking the natural miRNA synthesis could be an efficient RNAi strategy (Silva et al., 2005; Xia et al., 2006) . Our results clearly demonstrate that the modified mir-30a-based shRNA structure (sh2mir) had the strongest effect in silencing both exogenous and endogenous Ca v 1.2 (Fig. 2, C and D) .
Our data also confirmed that the EnSM22␣ promoter was vascularly selective in vitro (Fig. 4) . The EnSM22␣-EGFP-(sh2mir) 2 significantly reduced Ca v 1.2 expression and function in vascular smooth muscle cells (A7r5 cells, Fig. 5 ) but not in other cell types tested (Figs. 6 and 7) . Although Fig. 4B showed that there were a few GFP-expressing HL-1 cells when transfected with EnSM22␣-EGFP-(sh2mir) 2 , the expression and function of the L-type calcium channels in HL-1 cells (cardiomyocytes) were not affected because (sh2mir) 2 only targets the noncardiac form of Ca v 1.2 (Fig. 7) . This is very important because most calcium channel blockers are contraindicated in patients with heart failure because of potential adverse inotropic effects. Even the second generation dihydropyridines have been linked with an increased risk of cardiovascular events (Eisenberg et al., 2004) . Our study demonstrates the feasibility of selectively reducing vascular Ca v 1.2 expression and function without affecting cardiac Ca v 1.2 expression and function. This genetically based molecular intervention may potentially offer even higher vascular selectivity and fewer side effects than traditional dihydropyridines. However, we acknowledge that there is a long way to go from this in vitro study to a practical antihypertensive therapy. In vivo vascular selectivity, time course of gene transduction, efficiency of siRNA production, decrease in Ca V 1.2 expression and function in small resistance arteries, and corresponding changes in blood pressure all need to be carefully monitored and analyzed. A recent study showing in vivo application of shRNA expression cassette in zebrafish is encouraging (Su et al., 2008) , and we are currently working on the in vivo application of our constructs.
In summary, we screened several siRNA expression systems for tissue-selective delivery and found that a modified mir-30a-based shRNA structure (sh2mir) mediated the most effective silencing, which was enhanced by incorporating two copies of sh2mir. Furthermore, we demonstrated the feasibility of vascularly selective down-regulation of endogenous Ca v 1.2 expression and function in VSMCs without affecting cardiac Ca v 1.2 expression and function. Coupled with viral vectors, long-term, vascular smooth muscle-specific reduction of the noncardiac form of Ca v 1.2 expression in vivo may potentially improve patient outcomes for hypertension treatment.
